ANJAC Health & Beauty continues to strengthening its health-pharma division with a new strategic acquisition. The incorporation of HCG, a well-established Slovenian expert in nutraceuticals, allows the French manufacturer to further consolidate its range of innovative nutritional ingredients and products.
“The goal is to bridge food and supplementation to provide unique health solutions that are always backed with clinical studies,” said ANJAC in a press release.
The acquisition also enhances ANJAC’s commercial presence in high-potential markets across Central and Eastern Europe, as well as in Asia, the Middle East, and North America.
From ingredients to finished products
Based in Ljubljana, Slovenia, HCG is a leading international player in the food supplement market. Its fully integrated model allows the company to control the entire value chain from ingredients to finished products.
HCG operates through three complementary entities, giving it exceptional market strength: PharmaLinea, an expert in the development of turnkey food supplement solutions, backed by clinical studies and patented ingredients and technologies, and offering scientific and marketing consulting services to clients; Hermes Consilium, a creator and distributor of high-quality, branded ingredients for nutritional products; and ErgoPharma, the entity dedicated to industrial production.
Growth driver
HCG’s product portfolio covers several key therapeutic areas, including iron deficiency, women’s health, bone health and joint health, across the most in-demand market formats — liquids, capsules, powders, softgels, and more.
By leveraging this expertise and the commercial synergies between both groups, ANJAC Health & Beauty aims to accelerate its international growth with healthcare and pharmaceutical clients. The group also intends to apply HCG’s know-how to clinically validated beauty innovations.
Through ErgoPharma, HCG operates two R&D and manufacturing sites in Slovenia, certified FSSC 22000, GMP Food Supplement, ISO 14001, and FDA-compliant. The acquisition occurs in the context of a major investment program exceeding EUR 25 million, focused on expanding capacity and improving industrial efficiency at the Velenje new site. This will triple production capacity by the end of 2026, with additional growth potential beyond.
Through the acquisition of HCG, ANJAC further expands its portfolio of proprietary patents and clinical research.
HCG’s marketing, scientific and regulatory expertise, particularly through PharmaLinea, will enable ANJAC to support its clients from product conception to market launch, combining consumer insights, global trends, and distinctive clinical validation.
“This partnership reflects our strong ambitions in the health and pharma segment, our strategy in clinically backed food and nutraceuticals solutions and the continued acceleration of our international growth. We share with HCG a common vision: delivering innovative, high-performance solutions with a premium level of service recognized by our clients,” said Aurélien Chaufour, President of the ANJAC Group.
The HCG acquisition contributes EUR 30 million in additional revenue, supporting the ANJAC Health & Beauty group’s trajectory toward nearly EUR 800 million in 2025.
